These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38429698)

  • 61. Light-Induced Activation of a Specific Type-5 Metabotropic Glutamate Receptor Antagonist in the Ventrobasal Thalamus Causes Analgesia in a Mouse Model of Breakthrough Cancer Pain.
    Notartomaso S; Antenucci N; Liberatore F; Mascio G; Boccadamo Pompili SV; Font J; Scioli M; Luongo L; Arcella A; Gradini R; Llebaria A; Nicoletti F
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887364
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review.
    Mercadante S
    Crit Rev Oncol Hematol; 2018 Feb; 122():60-63. PubMed ID: 29458790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
    Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
    J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Dietrich E; Gums JG
    Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analyzing Differences in Perception between Oncologists and Patients to Adapt Pharmacological Treatment for Breakthrough Cancer Pain: Observational ADAPTATE Study.
    Cabezón-Gutiérrez L; Álamo-González C; Monge-Martín D; Caballero-Martínez F
    J Palliat Med; 2022 Jun; 25(6):925-931. PubMed ID: 35049361
    [No Abstract]   [Full Text] [Related]  

  • 67. [Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
    Lux EA; Schwittay A; Kleeberg UR; Papke J
    MMW Fortschr Med; 2018 Jul; 160(Suppl 4):18-23. PubMed ID: 29974433
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
    Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
    J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
    Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
    Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.
    Tekie Y; Nigatu YA; Mekonnen W; Berhe YW
    Front Oncol; 2023; 13():1248921. PubMed ID: 38264754
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fentanyl for the treatment of tumor-related breakthrough pain.
    Bornemann-Cimenti H; Wejbora M; Szilagyi IS; Sandner-Kiesling A
    Dtsch Arztebl Int; 2013 Apr; 110(16):271-7. PubMed ID: 23671467
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fentanyl for breakthrough cancer pain: where are we?
    Meriggi F; Zaniboni A
    Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
    Mercadante S
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
    [TBL] [Abstract][Full Text] [Related]  

  • 75. From "Breakthrough" to "Episodic" Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations.
    Løhre ET; Klepstad P; Bennett MI; Brunelli C; Caraceni A; Fainsinger RL; Knudsen AK; Mercadante S; Sjøgren P; Kaasa S;
    J Pain Symptom Manage; 2016 Jun; 51(6):1013-9. PubMed ID: 26921493
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study.
    López López R; Camps Herrero C; Khosravi-Shahi P; Guillem Porta V; Carrato Mena A; Garcia-Foncillas J; Cruz Hernández JJ; Gascón Vilaplana P; Antón Torres A; Diaz-Rubio E; Feyjoo Saus M; Aranda Aguilar E
    Clin Transl Oncol; 2018 May; 20(5):613-618. PubMed ID: 28975575
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study.
    Mercadante S; Masedu F; Valenti M; Aielli F
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32375331
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature.
    Deandrea S; Corli O; Consonni D; Villani W; Greco MT; Apolone G
    J Pain Symptom Manage; 2014 Jan; 47(1):57-76. PubMed ID: 23796584
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
    Davies A; Kleeberg UR; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Support Care Cancer; 2015 Jul; 23(7):2135-43. PubMed ID: 25556611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.